Photo Credit: RossHelen
The following is a summary of “Effect of Estimated Individual Vitreous Volume on Intraocular Pressure Spikes After Intravitreal Anti-Vascular Endothelial Growth Factors Injection,” published in the December 2024 issue of Ophthalmology by Koçak et al.
Researchers conducted a retrospective study to examine the effect of individual with estimated vitreous volume on intraocular pressure (IOP) spikes following intravitreal anti-vascular endothelial growth factor (VEGF) injections (IVI).
They calculated the vitreous volumes (VV) of eyes using an axial length (AL) based formula: AL3 × (π/6) × 0.76 + 0.012 × (AL – 24). The study eyes were classified into 4 groups based on the VV: <4.5 cm3 (Group 1, n = 52), 4.5–5.0 cm3 (Group 2, n = 60), 5.0–5.50 cm3 (Group 3, n = 60), and >5.50 cm3 (Group 4, n = 35). The IOP measurements were recorded at 5 time points: before the IVI, immediately after (post-IVI-0), 5 minutes (post-IVI-5), 15 minutes (post-IVI-15), and 30 minutes after the IVI.
The results showed a significant IOP changed across all 5 time points in all groups (P < 0.001 for all). When comparing measurements at the same time point between groups, a significant difference was only observed at the post-IVI-0 time point (P = 0.001). Post hoc analysis revealed that Group 1, Group 2, and Group 3 had higher IOP values than Group 4 (P < 0.05 for all). Additionally, patients treated with prefilled Ranibizumab syringes experienced lower IOP increases than those treated with vial-prepared Aflibercept injection at the post-IVI-0 time point (P = 0.042).
Investigators concluded an increase in IOP was observed across different initial intraocular volumes, the magnitude of which was lower in eyes with high volumes after IVI, and the PFS formulation demonstrated a reduced tendency for IOP elevation compared to vial-prepared forms.
